New strategy aims to outsmart antibodies blocking clotting treatment
NCT ID NCT02207894
First seen Apr 25, 2026 · Last updated Jun 23, 2026 · Updated 8 times
Summary
This study is testing a method called immune tolerance induction (ITI) to eliminate inhibitors—antibodies that block standard clotting factor treatment—in 300 people with haemophilia A. The approach uses high doses of clotting factor chosen specifically for each patient based on lab tests. The goal is to restore the effectiveness of factor VIII therapy and reduce bleeding episodes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HAEMOPHILIA A are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Haemophilia Centre Rhine Main
RECRUITINGFrankfurt am Main, Hesse, 60596, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Factor VIII concentrates (individualized selection) and high-dose immune tolerance induction (ITI)
What this could lead to
If successful, this approach could help haemophilia A patients with inhibitors regain normal clotting factor function, reducing bleeding risk.
What could go wrong
This is an observational study, not a controlled trial, so results may not prove cause and effect. Success rates vary, and some patients may not respond or may relapse.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.